Harnessing Molecular Glues for Next-Generation Vaccine, Cancer and Cardiovascular Disease Drug Development: A Comprehensive Review

Abbreviations

CVDs: Cardiovascular Diseases; PPIs: Protein-Protein Interactions; LNPs: Lipid Nanoparticles; IMiDs: Immunomodulatory Drugs; PCSK9: Proprotein Convertase Subtilisin/Kexin Type 9; LDL: Low-Density Lipoprotein.

Introduction

The rapid spread of the COVID-19 pandemic has spurred unprecedented global efforts to develop vaccines and therapeutics to mitigate its impact. This viral outbreak not only highlighted the urgency of addressing emergent infectious diseases but also underscored the limitations of existing vaccine platforms. Traditional vaccine technologies, while effective, face significant challenges such as prolonged development timelines, difficulties in large- scale manufacturing, and limited adaptability to rapidly evolving viral variants. Moreover, the logistical complexities associated with the distribution and administration of these vaccines, particularly in low-resource settings, has further emphasized the need for more versatile and resilient vaccine development strategies.

Simultaneously, cancer and cardiovascular diseases continue to impose a substantial burden on global public health systems. Cancer remains one of the leading causes of mortality worldwide, with millions of new cases diagnosed each year. The intricate nature of cancer, characterized by genetic heterogeneity and the ability of tumor cells to develop resistance to conventional therapies, necessitates innovative approaches for effective treatment. Traditional cancer therapies, including surgery, radiation, and chemotherapy, often lack specificity, leading to significant side effects and diminishing quality of life for patients. While targeted therapies and immunotherapies have made substantial strides in improving outcomes, the quest for more precise and adaptable treatment modalities persists.

Cardiovascular diseases (CVDs), encompassing conditions such as heart failure, atherosclerosis, and hypertension, remain the leading cause of death globally. The pathophysiology of CVDs involves complex molecular and cellular mechanisms, including dysregulated protein-protein interactions (PPIs) that govern critical processes like cardiac contractility, vascular tone regulation, and lipid metabolism. Despite advances in medical treatments and preventive strategies, the prevalence of CVDs continues to rise, driven by factors such as aging populations, lifestyle changes, and the increasing incidence of comorbidities like diabetes and obesity.

At the intersection of these pressing health challenges lies the emerging field of molecular glues small molecules that facilitate or stabilize specific PPIs. Unlike traditional small molecule inhibitors, which typically bind to a single protein target to block its function, molecular glues act as mediators that bring together two or more proteins, thereby modulating their interactions in a controlled manner. This unique mechanism of action allows molecular glues to target “undruggable” proteins that lack conventional binding sites, expanding the scope of therapeutic targets beyond what was previously feasible with existing drug modalities.

The significance of molecular glues extends across various domains of medicine, offering transformative potential in vaccine development, cancer therapy, and cardiovascular disease management. In the realm of vaccines, molecular glues can enhance the stability and delivery of vaccine components, improve antigen presentation, and modulate immune signaling pathways to elicit more robust and durable immune responses. For instance, in mRNA vaccine platforms, which have gained prominence due to their rapid development and high efficacy against COVID-19, molecular glues can stabilize lipid nanoparticles (LNPs) that encapsulate mRNA, thereby enhancing their stability and delivery efficiency. This stabilization is crucial for maintaining the integrity of mRNA molecules, preventing their degradation, and ensuring optimal antigen expression levels, which are essential for eliciting a strong immune response.

In cancer drug development, molecular glues offer a novel approach to target PPIs that are pivotal for tumor growth, survival, and metastasis. Traditional targeted therapies often face limitations related to specificity and the development of drug resistance. Molecular glues, by inducing or stabilizing specific PPIs, can lead to the selective degradation of oncogenic proteins or the disruption of critical signaling pathways within cancer cells. For example, immunomodulatory drugs (IMiDs) such as lenalidomide and pomalidomide act as molecular glues by binding to cereblon (CRBN), a component of the E3 ubiquitin ligase complex, thereby recruiting and degrading transcription factors essential for multiple myeloma cell survival. This targeted protein degradation not only disrupts vital survival pathways in cancer cells but also minimizes adverse effects on normal cells, enhancing the therapeutic index and patient tolerability.

Cardiovascular disease therapy also stands to benefit significantly from the application of molecular glues. PPIs play a crucial role in regulating numerous aspects of cardiovascular function, including cardiac contractility, vascular smooth muscle tone, and lipid metabolism. Dysregulation of these interactions can lead to pathological conditions such as heart failure, hypertension, and atherosclerosis. Molecular glues can modulate these interactions with high specificity, offering precise therapeutic interventions. For instance, molecular glues targeting proprotein convertase subtilisin/ kexin type 9 (PCSK9) can enhance its degradation, leading to increased levels of low-density lipoprotein (LDL) receptors and reduced LDL cholesterol levels, thereby mitigating the risk of atherosclerosis and associated cardiovascular events. Additionally, by stabilizing interactions involved in calcium signaling pathways, molecular glues can improve cardiac contractility and rhythm, offering potential treatments for heart failure and arrhythmias.

The versatility of molecular glues extends beyond these primary applications, offering potential benefits in the development of therapeutics for autoimmune disorders, neurodegenerative diseases, and other complex conditions where PPIs are dysregulated. The ability to precisely modulate PPIs opens new avenues for designing highly specific and effective treatments that can be tailored to individual patient profiles, aligning with the principles of precision medicine. Advances in high-throughput screening, computational modeling, and structural biology have accelerated the discovery and optimization of molecular glues, enabling the identification of compounds with desirable pharmacokinetic and pharmacodynamic properties.

Despite the promising potential of molecular glues, several challenges remain in their development and clinical application. Achieving the necessary specificity and selectivity to minimize off-target effects is paramount to ensuring safety and efficacy. Additionally, understanding the pharmacokinetics and pharmacodynamics of these molecules is essential for optimizing their therapeutic use. The stability, solubility, and bioavailability of molecular glues must be thoroughly evaluated to ensure their effectiveness in vivo. Furthermore, the complex nature of PPIs and the dynamic interplay between proteins necessitate a deep understanding of the underlying biology to design effective molecular glues.

Future research in the field of molecular glues is poised to address these challenges through the integration of innovative screening methods, advanced computational techniques, and a thorough exploration of the mechanistic underpinnings of PPIs. The continued development of next-generation molecular glues with enhanced specificity, broader target ranges, and improved drug-like properties will further expand their applicability and therapeutic efficacy. As the understanding of PPIs and their role in disease pathology deepens, molecular glues are likely to become integral components of the therapeutic arsenal, offering solutions to some of the most intractable health challenges of our time.

By examining the molecular mechanisms, recent advancements, and future prospects of molecular glue-based approaches, this review provides a thorough understanding of their transformative potential in combating infectious diseases, cancer, and cardiovascular ailments.

Vaccine Technologies: A Multifaceted Approach

The evolution of biomedical science has continuously sought innovative strategies to combat emerging and persistent health challenges, with infectious diseases, cancer, and cardiovascular disorders standing out as critical areas necessitating advanced therapeutic interventions. The COVID-19 pandemic, in particular, underscored the urgent need for rapid, adaptable, and effective solutions to emergent infectious threats, revealing both the potential and limitations of existing vaccine platforms. Traditional vaccine technologies, while effective, often grapple with prolonged development timelines, scalability issues, and limited adaptability to rapidly evolving viral variants. Additionally, the logistical complexities associated with the distribution and administration of these vaccines, especially in low-resource settings, has highlighted the necessity for more versatile and resilient vaccine development strategies. Concurrently, cancer remains one of the leading causes of mortality worldwide, characterized by its genetic heterogeneity and the ability of tumor cells to develop resistance to conventional therapies. Traditional cancer treatments, including surgery, radiation, and chemotherapy, often lack the specificity required to eliminate cancer cells without causing significant collateral damage to healthy tissues, thereby diminishing the quality of life for patients. Although targeted therapies and immunotherapies have made substantial strides in improving outcomes, the quest for more precise and adaptable treatment modalities persists. Similarly, cardiovascular diseases (CVDs), encompassing conditions such as heart failure, atherosclerosis, and hypertension, continue to impose a substantial burden on global public health systems, with their pathogenesis involving complex molecular mechanisms, including dysregulated protein- protein interactions (PPIs) that govern critical processes like cardiac contractility, vascular tone regulation, and lipid metabolism. Despite advances in medical treatments and preventive strategies, the prevalence of CVDs continues to rise, driven by factors such as aging populations, lifestyle changes, and the increasing incidence of comorbidities like diabetes and obesity.

At the intersection of these pressing health challenges lies the emerging field of molecular glues a novel class of small molecules designed to precisely modulate PPIs. Unlike traditional small molecule inhibitors that typically target a single protein to inhibit its function, molecular glues act as bridges, bringing together two or more proteins to facilitate or stabilize their interactions in a controlled manner. This unique mechanism allows for the selective degradation of disease-associated proteins or the stabilization of beneficial protein complexes, thereby offering a versatile approach to targeting previously inaccessible proteins. By inducing proximity-dependent effects such as ubiquitination and subsequent proteasomal degradation, molecular glues can effectively dismantle pathological protein networks or enhance protective ones, providing a powerful tool in the therapeutic arsenal. The significance of molecular glues is particularly evident in their ability to overcome the “undruggable” nature of many critical proteins involved in disease progression. This broadens the scope of therapeutic targets beyond what was previously feasible with existing drug modalities, enabling interventions that are both highly specific and efficacious. Moreover, molecular glues offer several advantages over traditional therapeutics, including a broader target scope, enhanced specificity, and a catalytic mode of action where a single molecule can induce multiple degradation events, thereby enhancing potency and reducing required dosages. Their versatility extends across various disease applications, from oncology to autoimmune disorders, neurodegenerative diseases, and infectious diseases, by modulating relevant PPIs with high precision.

In the realm of vaccine development, the advent of molecular glues holds significant promise in addressing key challenges related to antigen stability, efficient delivery, and robust immune stimulation. For instance, in mRNA vaccines, molecular glues can stabilize lipid nanoparticles (LNPs) that encapsulate mRNA, thereby enhancing their stability and delivery efficiency. This stabilization is crucial for maintaining the integrity of mRNA molecules, preventing their degradation, and ensuring optimal antigen expression levels, which are essential for eliciting a strong immune response. Additionally, in protein subunit vaccines, molecular glues can maintain the native conformation of viral proteins, enhancing their immunogenicity and ensuring a more effective immune response. This capability not only improves the efficacy of existing vaccine platforms but also facilitates the rapid adaptation of vaccines to emerging viral variants, thereby enhancing global health security.

In cancer therapy, molecular glues offer a transformative approach by enabling the selective degradation of oncogenic proteins that drive tumor growth and survival. Immunomodulatory drugs (IMiDs) such as lenalidomide and pomalidomide function as molecular glues by binding to cereblon (CRBN), a component of the E3 ubiquitin ligase complex, thereby recruiting and degrading transcription factors essential for multiple myeloma cell survival. This targeted degradation disrupts critical survival pathways in cancer cells while minimizing adverse effects on normal cells, thereby enhancing therapeutic efficacy and patient tolerability. Furthermore, the development of Proteolysis Targeting Chimeras (PROTACs) has expanded the scope of molecular glues in cancer treatment. PROTACs are bifunctional molecules that simultaneously bind to a target protein and an E3 ubiquitin ligase, effectively tagging the target protein for degradation by the proteasome. This strategy allows for the clearance of proteins previously deemed undruggable, such as transcription factors and scaffolding proteins, opening new avenues for cancer treatment and overcoming the limitations of traditional targeted therapies.

In the context of cardiovascular disease therapy, molecular glues provide a novel strategy to precisely modulate PPIs involved in critical aspects of cardiovascular function. For example, molecular glues targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) can enhance its degradation, leading to increased levels of low-density lipoprotein (LDL) receptors and reduced LDL cholesterol levels, thereby mitigating the risk of atherosclerosis and associated cardiovascular events. Additionally, molecular glues that stabilize interactions involved in calcium signaling pathways can improve cardiac contractility and rhythm, offering potential treatments for heart failure and arrhythmias. By targeting specific proteins involved in lipid metabolism and calcium homeostasis, molecular glues can provide more targeted and effective interventions for a variety of cardiovascular conditions, addressing the intricate molecular underpinnings that drive these diseases.

The integration of molecular glues into precision medicine frameworks further amplifies their therapeutic potential by enabling highly personalized interventions tailored to an individual’s genetic, molecular, and clinical profiles. Precision medicine aims to deliver treatments that align with the unique molecular landscape of each patient’s condition, thereby maximizing therapeutic efficacy while minimizing adverse effects. Advances in high-throughput screening, computational modeling, and structural biology have been instrumental in identifying and optimizing molecular glues with desirable pharmacokinetic and pharmacodynamic properties, facilitating the development of highly selective and potent therapeutic agents. This alignment with precision medicine principles ensures that treatments are not only effective but also bespoke to the patient’s specific disease context, enhancing overall patient outcomes and advancing the frontiers of personalized healthcare.

Despite their immense potential, several challenges must be addressed to fully realize the therapeutic benefits of molecular glues. Achieving the necessary specificity and selectivity to minimize off-target effects is paramount to ensuring safety and efficacy. Additionally, understanding the pharmacokinetics and pharmacodynamics of these molecules is essential for optimizing their therapeutic use. The stability, solubility, and bioavailability of molecular glues must be thoroughly evaluated to ensure their effectiveness in vivo. Moreover, the complex nature of PPIs and the dynamic interplay between proteins necessitate a deep understanding of the underlying biology to design effective molecular glues.

Future research in the field of molecular glues is poised to address these challenges through the integration of innovative screening methods, advanced computational techniques, and a thorough exploration of the mechanistic underpinnings of PPIs. The continued development of next-generation molecular glues with enhanced specificity, broader target ranges, and improved drug-like properties will further expand their applicability and therapeutic efficacy. As the understanding of PPIs and their role in disease pathology deepens, molecular glues are likely to become integral components of the therapeutic arsenal, offering solutions to some of the most intractable health challenges of our time.

By harnessing the power of PPIs, molecular glues enable the precise modulation of critical biological processes, paving the way for more effective and personalized treatments. As research continues to advance our understanding of molecular glues and their mechanisms of action, their integration into various domains of medicine is poised to revolutionize the landscape of therapeutic interventions, addressing some of the most pressing health challenges of our time.

Molecular Glues in Vaccine Formulation: Mechanisms and Applications

Building upon the foundational understanding of molecular glues and their transformative potential in various therapeutic domains, the subsequent sections of this review delve deeper into the specific applications of molecular glues in vaccine formulation, cancer therapy, and cardiovascular disease (CVD) treatment. The first focal point is the exploration of molecular glues in vaccine formulation, where the intricate mechanisms of action are meticulously examined. Molecular glues function by stabilizing protein- protein interactions (PPIs), thereby enhancing the stability, immunogenicity, and delivery efficiency of vaccine components. This stabilization is crucial for maintaining the integrity and functionality of vaccine antigens, which are essential for eliciting a robust and sustained immune response. By promoting the formation of antigen-presenting complexes, molecular glues facilitate the efficient display of antigens to immune cells, thereby potentiating immune responses against viral pathogens. Additionally, molecular glues play a pivotal role in modulating immune signaling pathways, further augmenting the vaccine-induced immunity. These mechanisms collectively contribute to the increased efficacy and durability of vaccines, ensuring that they can provide long-lasting protection against infectious diseases.

The applications of molecular glues in vaccine development are multifaceted, offering numerous benefits that address some of the most pressing challenges in modern vaccine technology. One of the primary advantages is the increased stability of vaccine components, which is particularly important for vaccines that require stringent storage conditions, such as mRNA vaccines. By stabilizing lipid nanoparticles (LNPs) that encapsulate mRNA, molecular glues enhance the delivery efficiency of these vaccines, ensuring that the mRNA remains intact and functional until it reaches the target cells. This not only improves the overall effectiveness of the vaccine but also reduces the need for ultra-cold storage, thereby facilitating wider distribution and accessibility, especially in low-resource settings. Moreover, molecular glues enhance the immunogenicity of vaccines by maintaining the native conformation of viral proteins, which is critical for the proper recognition and response by the immune system. This enhanced immunogenicity translates to stronger and more consistent immune responses, providing more reliable protection against viral infections.

Furthermore, the integration of molecular glues in vaccine development offers adaptability to emerging viral variants, a crucial attribute in the face of rapidly mutating pathogens. As new variants of viruses emerge, the ability to swiftly adjust and optimize vaccine formulations is essential for maintaining their effectiveness. Molecular glues enable these rapid adjustments by stabilizing and enhancing the delivery of updated vaccine components, ensuring that vaccines remain effective against new strains. This adaptability is particularly significant in the context of global health crises, where the timely development and deployment of effective vaccines can have a profound impact on controlling disease spread and reducing mortality rates.

In addition to the extensive discussion on molecular glues in vaccine formulation, the review also encompasses their application in cardiovascular disease therapy, presented comprehensively in Table 3. This table provides an overview of various molecular glues targeting key proteins involved in cardiovascular pathologies, highlighting their mechanisms of action, therapeutic applications, and current clinical statuses. For instance, PCSK9 inhibitors represent a significant advancement in the management of hypercholesterolemia and atherosclerosis. By enhancing the degradation of PCSK9, these molecular glues increase the levels of low-density lipoprotein (LDL) receptors, thereby reducing LDL cholesterol levels and mitigating the risk of plaque formation in arterial walls. This targeted approach not only improves lipid metabolism but also offers a novel strategy for preventing cardiovascular events associated with elevated cholesterol levels.

Calcium signaling modulators, another critical category of molecular glues, target proteins involved in calcium homeostasis, which is fundamental for maintaining normal cardiac rhythm and contractility. By stabilizing interactions that promote proper calcium signaling, these molecular glues offer potential treatments for cardiac arrhythmias and heart failure, conditions that stem from disrupted calcium dynamics. The stabilization of these interactions ensures that calcium ions are appropriately regulated within cardiac cells, thereby improving myocardial function and reducing the incidence of arrhythmias, which are significant contributors to cardiovascular morbidity and mortality.

Lipid metabolism regulators, as detailed in Table 3, focus on proteins that govern lipid processing and storage within the body. Molecular glues designed to degrade pro- atherogenic factors or stabilize anti-atherogenic proteins can effectively reduce lipid accumulation in arterial walls, thereby preventing the progression of atherosclerosis. This targeted degradation approach not only addresses the underlying molecular mechanisms driving lipid accumulation but also offers a preventive strategy against the development of more severe cardiovascular conditions such as heart attacks and strokes.

The therapeutic applications of molecular glues extend beyond stabilization and degradation of proteins; they also encompass modulation of complex metabolic pathways that are dysregulated in diseases. For instance, by targeting specific enzymes or receptors involved in lipid metabolism, molecular glues can alter the metabolic fluxes, leading to improved lipid profiles and reduced cardiovascular risk factors. The clinical status of these molecular glues varies, with some, like PCSK9 inhibitors, already approved and in widespread use, while others are in preclinical or clinical trial phases, underscoring the ongoing research and development efforts aimed at expanding the therapeutic repertoire of molecular glues.

In summary, the upcoming sections of this review provide a detailed examination of how molecular glues enhance vaccine formulation through mechanisms that stabilize and improve the delivery and immune response of vaccine components. Additionally, the inclusion of Table 3 offers a comprehensive overview of the role of molecular glues in cardiovascular disease therapy, detailing their target proteins, mechanisms of action, therapeutic applications, and clinical statuses. This multifaceted exploration underscores the versatility and transformative potential of molecular glues in addressing some of the most critical health challenges of our time, highlighting their role in advancing precision medicine and improving patient outcomes across a spectrum of diseases. As the field of molecular glues continues to evolve, their integration into vaccine technologies and cardiovascular disease treatments exemplifies the innovative strides being made in drug development, promising a future where highly specific and effective therapeutic interventions are not only possible but are becoming a reality.

Conclusion

The advent of molecular glues has ushered in a new era in therapeutic development, offering unprecedented opportunities to target complex protein-protein interactions (PPIs) that were previously deemed “undruggable.” In the realm of cancer therapy, molecular glues such as cereblon modulators exemplify the profound impact of this innovative approach. Thalidomide analogs like lenalidomide and pomalidomide have revolutionized the treatment of multiple myeloma by binding to the cereblon (CRBN) E3 ubiquitin ligase complex, thereby altering its substrate specificity to degrade crucial transcription factors Ikaros and Aiolos [18, 19, 20]. This targeted protein degradation not only disrupts cancer cell survival pathways but also minimizes adverse effects on healthy cells, enhancing the therapeutic index and patient tolerability.

Further expanding the scope of molecular glues in oncology are Proteolysis-Targeting Chimeras (PROTACs), a novel class designed to degrade specific proteins by simultaneously binding to a target protein and an E3 ubiquitin ligase. PROTACs such as ARV-110 and ARV- 471 have shown remarkable promise in clinical settings, targeting the androgen receptor in metastatic castration- resistant prostate cancer and the estrogen receptor in breast cancer, respectively Neklesa T, et al. [23] and Snyder LB, et al. [24]. These bifunctional molecules exemplify the versatility of PROTAC technology, offering a potent means to eliminate oncogenic proteins that drive tumor progression. Additionally, recent advancements have introduced molecular glues that selectively degrade SMARCA2/4, key components of the SWI/SNF chromatin remodeling complex implicated in various cancers [26]. By exploiting the dependency of cancer cells on these proteins, SMARCA2/4 degraders provide a targeted therapeutic approach with reduced off-target toxicity, further showcasing the precision and efficacy of molecular glues in cancer treatment.

In the field of cardiovascular disease (CVD) therapy, molecular glues represent a new frontier with the potential to address some of the most challenging aspects of heart health. Cardiovascular diseases, including heart failure, atherosclerosis, and hypertension, remain the leading causes of morbidity and mortality worldwide, driven by intricate molecular mechanisms involving dysregulated PPIs. Molecular glues can modulate these interactions, providing precise therapeutic interventions that enhance cardiac contractility, regulate vascular tone, and improve lipid metabolism. For instance, targeting cardiac contractility involves molecular glues that stabilize interactions between cardiac troponin and other contractile proteins, thereby enhancing myocardial function and preventing heart failure progression [17]. Similarly, in the management of hypertension, molecular glues targeting proteins that regulate smooth muscle contraction and relaxation offer a novel approach to modulate vascular tone, ensuring precise control over blood pressure [27].

A notable case study in cardiovascular therapy is the targeting of proprotein convertase subtilisin/kexin type 9 (PCSK9), a key regulator of low-density lipoprotein (LDL) receptor degradation. Molecular glues enhancing the degradation of PCSK9 can increase LDL receptor levels, thereby reducing LDL cholesterol and mitigating the risk of atherosclerosis [28]. Approved PCSK9 inhibitors, such as Alirocumab, exemplify the clinical viability of molecular glues in managing hypercholesterolemia and preventing cardiovascular events. Additionally, molecular glues that modulate calcium signaling pathways involved in cardiac arrhythmias and heart failure offer substantial promise. By stabilizing interactions that promote normal cardiac rhythm and contractility, these molecular glues can significantly improve cardiac function and reduce the burden of heart failure and arrhythmias from Zhang Y, et al. [17].

Despite the remarkable advancements, the application of molecular glues in both cancer and cardiovascular therapies is not without challenges. Identifying suitable targets and designing effective molecular glues with high specificity and selectivity remains a primary hurdle. Off-target effects can lead to unintended consequences, underscoring the need for meticulous molecular design and thorough pharmacokinetic and pharmacodynamic evaluations. Additionally, the stability, solubility, and bioavailability of molecular glues must be optimized to ensure their effectiveness in vivo. Understanding the long-term impacts of these therapies on cardiovascular and overall health is crucial to their successful clinical application [29, 30, 31, 32, 33, 34].

Looking forward, the future of molecular glues is bright, with ongoing research focused on expanding their repertoire through innovative screening methods and computational approaches. High-throughput screening and advanced computational modeling are integral to identifying new molecular glues that can target a broader range of PPIs with enhanced efficacy and safety profiles. Furthermore, elucidating the detailed mechanisms of action of existing molecular glues will provide deeper insights into their therapeutic potential, guiding the development of next-generation compounds with improved properties. The integration of molecular glues into precision medicine frameworks holds significant promise, enabling highly personalized treatments tailored to individual genetic and molecular profiles. This alignment with precision medicine principles ensures that therapies are not only effective but also minimize adverse effects, thereby enhancing patient outcomes and advancing the fields of oncology, immunology, and cardiovascular medicine [35, 36, 37, 38].

In conclusion, molecular glues represent a revolutionary approach in the development of next-generation vaccines, cancer therapeutics, and cardiovascular disease treatments. By enabling the precise targeting and modulation of critical protein-protein interactions, molecular glues offer novel therapeutic strategies characterized by high specificity and reduced side effects. The successful case studies in cancer therapy, including cereblon modulators, PROTACs, and SMARCA2/4 degraders, alongside the promising applications in cardiovascular disease therapy, highlight the versatile and transformative potential of molecular glues. As research continues to advance, the integration of molecular glues into precision medicine and vaccine technologies is poised to significantly improve patient outcomes, addressing some of the most pressing health challenges of our time. The continued exploration and development of molecular glues hold great promise for revolutionizing the landscape of therapeutic interventions, ultimately contributing to the advancement of global health and well-being [39, 40, 41, 42, 43, 44, 45].

Molecular glues represent a revolutionary approach in both vaccine development and cancer drug discovery by enabling the targeting of protein-protein interactions critical for immune responses and cancer progression. Their ability to induce selective degradation of oncogenic proteins and stabilize vaccine components offers novel therapeutic strategies with the potential for high specificity and reduced side effects. Additionally, the application of molecular glues in cardiovascular disease therapy opens new avenues for treating conditions such as heart failure, atherosclerosis, and hypertension [46, 47, 48, 49].

As research progresses, the integration of molecular glues into precision medicine and vaccine technologies will likely lead to more effective and personalized treatments, ultimately improving patient outcomes and advancing the fields of oncology, immunology, and cardiovascular medicine. The continued exploration and development of molecular glues hold great promise for addressing some of the most pressing health challenges of our time, revolutionizing the landscape of therapeutic interventions.